Thien Nhan Lu - Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences

Thien Nhan Lu

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences

Melbourne City | Australia

Additional Specialties: Organic chemistry, Medicinal chemistry, Cancer research

ORCID logohttps://orcid.org/0000-0003-1549-7665

Thien Nhan Lu - Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences

Thien Nhan Lu

Introduction

Primary Affiliation: Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences - Melbourne City , Australia

Additional Specialties:

Education

Mar 2013 - Mar 2015
Kangwon National University, South Korea
Master of Science in Pharmacy
College of Pharmacy
Sep 2007 - Oct 2012
Ho Chi Minh City University of Medicine and Pharmacy, Vietnam
Degree of Pharmacist
Faculty of Pharmacy, department of Organic Chemistry

Experience

Aug 2019
Monash University (Australia)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences
Jan 2018 - Jan 2018
Ho Chi Minh City University of Technology
Lecturer
Faculty of Pharmacy
Oct 2016 - Dec 2017
Ho Chi Minh City University of Medicine and Pharmacy
Researcher
Organic Chemistry Department, Faculty of Pharmacy
Mar 2015 - Oct 2016
Kangwon National University
Researcher (Research Advisor: Prof. Jongkook Lee)
College of Pharmacy

Publications

3Publications

179Reads

57Profile Views

1PubMed Central Citations

Antitumor effect of the integrin α4 signaling inhibitor JK273 in non-small cell lung cancer NCI-H460 cells.

Biochem Biophys Res Commun 2017 09 17;491(2):355-360. Epub 2017 Jul 17.

College of Pharmacy, Kangwon National University, 1 Kangwondaehak-gil, Chuncheon, Gangwon-do 24341, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2017.07.096DOI Listing
September 2017
127 Reads
1 Citation
2.300 Impact Factor

First Syntheses of (+/-)-Butesuperins A and B

Bull. Korean Chem. Soc. 2017 August 16; 38(8): 944-947

Bulletin of the Korean Chemical Society

In conclusion, we have successfully achieved the first syntheses of (+/-)-butesuperins A (1) and B (2), which employ oxidative coupling as a key step and can provide large quantities of these isoflavonolignans. Our results show that potassium ferricyanide (K3Fe(CN)6) followed by K2CO3 isomerization was the most efficient among all the oxidative coupling methods examined in producing (+/-)-butesuperins A (1) and B (2). Butesuperin A (1) showed moderate antiproliferative activity, which suggests that butesuperin A (1) will serve as a lead for new cancer therapeutics. These synthesized compounds will be used as reference standards to establish a screening method for the detection of Butea Superba root in dietary supplements. Considering that butesuperins A (1) and B (2) can be isolated only in small amounts from natural sources (approximately 2.0 mg from 2.4 kg of the dried Butea Superba root),1 these syntheses should offer a highly efficient source. Pharmacological and toxicological evaluation of synthetic (+/-)-butesuperins A (1) and B (2) are also currently underway, and the results will be reported in due course.

View Article
August 2017
9 Reads